Related Experiment Video
Updated: Jan 15, 2026

Osteoclast Derivation from Mouse Bone Marrow
Published on: November 6, 2014
The interrelationship between prostate cancer and osteoporosis: new perspectives on shared molecular pathways and
Zesong Jiang1,2, Junwen Zhang1,2, Zhongjian Qiu1,2
1Department of Urology, Affiliated Hospital of Jining Medical University, Jining, Shandong, China.
Abstract:
Osteoporosis is frequently regarded as a complication associated with androgen deprivation therapy (ADT) in patients with prostate cancer. Nevertheless, a notably higher incidence of osteoporosis has been observed in prostate cancer patients even in the absence of ADT, when compared to age-matched healthy individuals. This phenomenon is likely attributable to the synergistic effects of aging, chronic inflammation, and tumor-related factors, which collectively contribute to accelerated bone loss in this population. Accumulating evidence has demonstrated that signaling pathways such as RANKL/RANK/OPG, Wnt, CXCL12/CXCR4, TGF-β, and IGF-1, play critical roles in both prostate cancer and osteoporosis. These pathways may provide potential targets for the concurrent treatment of the two diseases. Despite this, existing reviews have provided only limited examination of the overlapping molecular mechanisms underpinning both diseases. This review aims to elucidate the interplay between osteoporosis and prostate cancer, offering a comprehensive analysis of the shared signaling pathways implicated in the progression of both conditions. In addition, prevailing treatment strategies for the prevention of osteoporosis in prostate cancer patients are evaluated, and the potential for the development of dual-action pharmacological agents targeting the RANKL/RANK/OPG, Wnt, and CXCL12/CXCR4 pathways is discussed. These emerging approaches may yield more effective therapeutic modalities for individuals with prostate cancer.
More Related Videos
06:32Intra-Cardiac Injection of Human Prostate Cancer Cells to Create a Bone Metastasis Xenograft Mouse Model
Published on: November 4, 2022
07:25A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Osteoclasts in Bone Remodeling
Bone Disorders
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Bone Remodeling